Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Shares Outstanding (Weighted Average) (2022 - 2026)

Sagimet Biosciences' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $32.6 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.13% to $32.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $32.6 million through Mar 2026, up 1.13% year-over-year, with the annual reading at $32.3 million for FY2025, 3.17% up from the prior year.
  • Shares Outstanding (Weighted Average) came in at $32.6 million for Q1 2026, up from $32.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $32.6 million in Q1 2026 to a low of $79545.0 in Q4 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $30.2 million (2024), against an average of $19.7 million.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 16739.32% in 2024 and then grew 0.88% in 2025.
  • Sagimet Biosciences' Shares Outstanding (Weighted Average) stood at $79545.0 in 2022, then skyrocketed by 13050.21% to $10.5 million in 2023, then soared by 199.71% to $31.4 million in 2024, then grew by 3.17% to $32.3 million in 2025, then grew by 0.66% to $32.6 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Shares Outstanding (Weighted Average) are $32.6 million (Q1 2026), $32.3 million (Q4 2025), and $32.5 million (Q3 2025).